POET's High-Stakes Bet: $400M Capital Raise, a 22% Stock Rout, and a Client Worth Half a Billion

POET Technologies secures $400M for AI optical hardware, but stock drops 22% on dilution fears and shareholder class-action lawsuits. Revenue doubles but losses widen.

POET Technologies finds itself in a precarious balancing act. The company has secured a $400 million capital injection to accelerate its push into optical hardware for AI, but the move has triggered a sharp sell-off and opened the door to a wave of shareholder litigation. For existing investors, the math is brutal: more cash today means significant dilution tomorrow, and the stock took a 22.36 percent hit on Friday, settling at $15.97.

The placement came at a premium — $21.00 per unit, each consisting of one common share and a three-year warrant exercisable at $26.15 — but that did little to cushion the blow. The shares had rallied 45.8 percent in the week leading up to May 17, making the correction all the more jarring. Post-plunge, the company’s market capitalisation stood at roughly $1.4 billion, a steep discount to the valuation it commanded just days earlier.

Operations: Revenue climbs, but losses persist

First-quarter results offered a glimpse of progress, though profitability remains distant. Revenue hit $503,389, more than double the $166,760 reported a year earlier and well above the consensus estimate of $250,000. The increase was tied to initial phases of new technology agreements. Yet the net loss widened to $0.08 per share — worse than the $0.05 analysts had forecast — and operating cash flow stayed in the red at negative $8.8 million.

At current run rates, the company’s price-to-revenue multiple is extreme. The last twelve months of sales amounted to about $1.1 million, meaning the $1.4 billion market cap implies a multiple north of 1,200. That kind of premium can only be justified if the commercial ramp happens quickly.

The Lumilens bet: $50 million now, $500 million later

The real driver of the growth narrative is a partnership with Lumilens. The customer placed an initial order worth $50 million for POET’s optical interconnect platform, and the agreement could expand to cumulative purchases of more than $500 million over five years. Engineering samples are slated for late 2026, with volume production tied to hyperscaler projects in 2027.

But the deal comes with its own dilution: POET granted Lumilens warrants for 22.9 million shares at an exercise price of $8.25, with a nine-year term. A portion is immediately exercisable. That adds another layer of potential share count expansion on top of the placement.

Meanwhile, the company suffered a blow from Marvell, which after acquiring Celestial AI, cancelled all outstanding orders from that unit, citing alleged breaches of confidentiality. That loss leaves Lumilens as the dominant commercial pillar.

Class actions and a leadership shake-up

Legal troubles are piling up. Multiple class-action suits were filed on Sunday, May 17, covering purchases made between April 1 and April 27. The plaintiffs accuse POET of misleading statements and omissions, particularly around its possible status as a passive foreign investment company under US tax law. They also allege that former CFO Thomas Mika made public comments that violated a confidentiality agreement and jeopardised business prospects.

Mika, who had served as finance chief for ten years, is retiring. Sandeep Kumar steps into the new role of chief operating officer, tasked with overseeing the production ramp. The board has also approved a plan to redomicile the company to the United States and convert it into a US corporation — a move likely to be put to a vote at the annual meeting on June 26, 2026.

Investors who want to serve as lead plaintiff in the securities litigation have until June 29 to file. To mitigate potential tax disadvantages for US shareholders, POET says it will provide information for a QEF election for fiscal 2025.

The convergence of a massive capital raise, pending lawsuits, and a single make-or-break customer means the next 12 months will be decisive. POET must now deliver on the Lumilens ramp and the next generation of 800G and 1.6T pluggable transceivers — or face the consequences of a story that has already priced in exponential growth.